Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Gynecology

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 66 articles:
HTML format
Text format



Single Articles


    October 2019
  1. KANAKKANTHARA A, Kurmi K, Ekstrom TL, Hou X, et al
    BRCA1 Deficiency Upregulates NNMT Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents.
    Cancer Res. 2019 Oct 16. pii: 0008-5472.CAN-19-1405.
    PubMed     Text format     Abstract available


  2. CARBONE M, Melino G
    Stearoyl CoA Desaturase Regulates Ferroptosis in Ovarian Cancer Offering New Therapeutic Perspectives.
    Cancer Res. 2019;79:5149-5150.
    PubMed     Text format     Abstract available


    September 2019
  3. CHUI MH, Doodnauth SA, Erdmann N, Tiedemann RE, et al
    Chromosomal instability and mTORC1 activation through PTEN loss contribute to proteotoxic stress in ovarian carcinoma.
    Cancer Res. 2019 Sep 17. pii: 0008-5472.CAN-18-3029.
    PubMed     Text format     Abstract available


  4. ROBERTS AL, Huang T, Koenen KC, Kim Y, et al
    Posttraumatic stress disorder (PTSD) is associated with increased risk of ovarian cancer: a prospective and retrospective longitudinal cohort study.
    Cancer Res. 2019 Sep 5. pii: 0008-5472.CAN-19-1222.
    PubMed     Text format     Abstract available


    August 2019
  5. PERES LC, Mallen AR, Townsend MK, Poole EM, et al
    High levels of C-reactive protein are associated with an increased risk of ovarian cancer: Results from the Ovarian Cancer Cohort Consortium.
    Cancer Res. 2019 Aug 28. pii: 0008-5472.CAN-19-1554.
    PubMed     Text format     Abstract available


  6. HAINES K, Huang GS
    Precision Therapy for Aggressive Endometrial Cancer by Reactivation of Protein Phosphatase 2A.
    Cancer Res. 2019;79:4009-4010.
    PubMed     Text format     Abstract available


    July 2019
  7. SHANG S, Yang J, Jazaeri AA, Duval AJ, et al
    Chemotherapy-induced distal enhancers drive transcriptional program to maintain the chemoresistant state in ovarian cancer.
    Cancer Res. 2019 Jul 29. pii: 0008-5472.CAN-19-0215.
    PubMed     Text format     Abstract available


  8. FUKUMOTO T, Fatkhutdinov N, Zundell JA, Tcyganov EN, et al
    HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer.
    Cancer Res. 2019 Jul 16. pii: 0008-5472.CAN-19-1302.
    PubMed     Text format     Abstract available


  9. ARROYO-MUHR LS, Lagheden C, Hultin E, Eklund C, et al
    The HPV16 genome is stable in women who progress to in situ or invasive cervical cancer: a prospective population-based study.
    Cancer Res. 2019 Jul 9. pii: 0008-5472.CAN-18-3933.
    PubMed     Text format     Abstract available


  10. TESFAY L, Paul BT, Konstorum A, Deng Z, et al
    Steroyl-CoA Desaturase 1 (SCD1) protects ovarian cancer cells from ferroptotic cell death.
    Cancer Res. 2019 Jul 3. pii: 0008-5472.CAN-19-0369.
    PubMed     Text format     Abstract available


    June 2019
  11. LU D, Andrae B, Valdimarsdottir U, Sundstrom K, et al
    Psychological distress is associated with cancer-specific mortality among patients with cervical cancer.
    Cancer Res. 2019 Jun 28. pii: 0008-5472.CAN-19-0116.
    PubMed     Text format     Abstract available


    May 2019
  12. TAYLOR SE, O'Connor CM, Wang Z, Shen G, et al
    The highly recurrent PP2A Aalpha-subunit mutation P179R alters protein structure and impairs PP2A enzyme function to promote endometrial tumorigenesis.
    Cancer Res. 2019 May 29. pii: 0008-5472.CAN-19-0218.
    PubMed     Text format     Abstract available


  13. MUYS BR, Sousa JF, Placa JR, Araujo LF, et al
    miR-450a acts as a tumor suppressor in ovarian cancer by regulating energy metabolism.
    Cancer Res. 2019 May 17. pii: 0008-5472.CAN-19-0490.
    PubMed     Text format     Abstract available


  14. DORAYAPPAN KDP, Gardner ML, Hisey CL, Zingarelli RA, et al
    A microfluidic chip enables isolation of exosomes and establishment of their protein profiles and associated signaling pathways in ovarian cancer.
    Cancer Res. 2019 May 16. pii: 0008-5472.CAN-18-3538.
    PubMed     Text format     Abstract available


  15. TRAVERS M, Brown SM, Dunworth M, Holbert CE, et al
    DFMO and 5-azacytidine increase M1 macrophages in the tumor microenvironment of murine ovarian cancer.
    Cancer Res. 2019 May 14. pii: 0008-5472.CAN-18-4018.
    PubMed     Text format     Abstract available


  16. MUKHERJEE A, Huynh V, Gaines K, Reh WA, et al
    Targeting the High Mobility Group Box 3 protein sensitizes chemoresistant ovarian cancer cells to cisplatin.
    Cancer Res. 2019 May 6. pii: 0008-5472.CAN-19-0542.
    PubMed     Text format     Abstract available


    March 2019
  17. PRICE C, Gill S, Ho ZV, Davidson SM, et al
    Genome-wide interrogation of human cancers identifies EGLN1 dependency in clear cell ovarian cancers.
    Cancer Res. 2019 Mar 21. pii: 0008-5472.CAN-18-2674.
    PubMed     Text format     Abstract available


  18. SRIVASTAVA AK, Banerjee A, Cui T, Han C, et al
    Inhibition of miR-328-3p impairs cancer stem cell function and prevents metastasis in ovarian cancer.
    Cancer Res. 2019 Mar 20. pii: 0008-5472.CAN-18-3668.
    PubMed     Text format     Abstract available


  19. NATARAJAN S, Foreman KM, Soriano MI, Rossen NS, et al
    Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian cancer metastasis.
    Cancer Res. 2019 Mar 12. pii: 0008-5472.CAN-18-2616.
    PubMed     Text format     Abstract available


    February 2019
  20. CHOI J, Brown KM
    A Dynamic Cis-Regulation Pattern Underlying Epithelial Ovarian Cancer Susceptibility.
    Cancer Res. 2019;79:439-440.
    PubMed     Text format     Abstract available


    January 2019
  21. WALCH-RUCKHEIM B, Stroder R, Theobald L, Pahne-Zeppenfeld J, et al
    Cervical cancer-instructed stromal fibroblasts enhance IL-23 expression in dendritic cells to support expansion of Th17 cells.
    Cancer Res. 2019 Jan 29. pii: 0008-5472.CAN-18-1913.
    PubMed     Text format     Abstract available


  22. YAGI A, Ueda Y, Kakuda M, Tanaka Y, et al
    Epidemiological and clinical analyses of cervical cancer using data from the population-based Osaka cancer registry.
    Cancer Res. 2019 Jan 11. pii: 0008-5472.CAN-18-3109.
    PubMed     Text format     Abstract available


    December 2018
  23. HOODA J, Novak M, Salomon MP, Matsuba C, et al
    Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer.
    Cancer Res. 2018 Dec 18. pii: 0008-5472.CAN-18-2297.
    PubMed     Text format     Abstract available


  24. YANG Y, Wu L, Shu X, Lu Y, et al
    Genetic data from nearly 63,000 women of European descent predicts DNA methylation biomarkers and epithelial ovarian cancer risk.
    Cancer Res. 2018 Dec 17. pii: 0008-5472.CAN-18-2726.
    PubMed     Text format     Abstract available


    November 2018
  25. BUCKLEY MA, Woods NT, Tyrer JP, Mendoza-Fandino G, et al
    Functional analysis and fine mapping of the 9p22.2 ovarian cancer susceptibility locus.
    Cancer Res. 2018 Nov 28. pii: 0008-5472.CAN-17-3864.
    PubMed     Text format     Abstract available


  26. POLUSANI SR, Huang YW, Huang G, Chen CW, et al
    Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer.
    Cancer Res. 2018 Nov 2. pii: 0008-5472.CAN-18-1615.
    PubMed     Text format     Abstract available


    October 2018

  27. Correction: RSF1 Is a Positive Regulator of NFkappaB-induced Gene Expression Required for Ovarian Cancer Chemoresistance.
    Cancer Res. 2018;78:6024.
    PubMed     Text format    


    September 2018
  28. LIU M, Thomas SL, DeWitt AK, Zhou W, et al
    Dual inhibition of DNA and histone methyltransferases increases viral mimicry in ovarian cancer cells.
    Cancer Res. 2018 Sep 5. pii: 0008-5472.CAN-17-3953.
    PubMed     Text format     Abstract available


    August 2018
  29. BYEON Y, Lee JW, Choi WS, Won JE, et al
    CD44-targeted PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer.
    Cancer Res. 2018 Aug 16. pii: 0008-5472.CAN-17-3871.
    PubMed     Text format     Abstract available



  30. Correction: Significance of MAD2 Expression to Mitotic Checkpoint Control in Ovarian Cancer Cells.
    Cancer Res. 2018;78:4800.
    PubMed     Text format    


  31. BELANGER F, Fortier E, Dube M, Lemay JF, et al
    Replication Protein A Availability During DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in Ovarian Cancer Cells.
    Cancer Res. 2018 Aug 2. pii: 0008-5472.CAN-18-0618.
    PubMed     Text format     Abstract available


    July 2018
  32. LU Y, Beeghly-Fadiel A, Wu L, Guo X, et al
    A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk.
    Cancer Res. 2018 Jul 27. pii: 0008-5472.CAN-18-0951.
    PubMed     Text format     Abstract available



  33. Correction: Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma.
    Cancer Res. 2018;78:4100.
    PubMed     Text format    



  34. Correction: Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer.
    Cancer Res. 2018;78:4099.
    PubMed     Text format    



  35. Correction: FIH Is an Oxygen Sensor in Ovarian Cancer for G9a/GLP-Driven Epigenetic Regulation of Metastasis-Related Genes.
    Cancer Res. 2018;78:3742.
    PubMed     Text format    


    June 2018

  36. Correction: Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells.
    Cancer Res. 2018;78:3402.
    PubMed     Text format    


  37. HIRST J, Pathak HB, Hyter S, Pessetto ZY, et al
    Licofelone enhances the efficacy of paclitaxel in ovarian cancer by reversing drug resistance and tumor stem-like properties.
    Cancer Res. 2018 Jun 11. pii: 0008-5472.CAN-17-3993.
    PubMed     Text format     Abstract available


    May 2018
  38. HAUTANIEMI S, Kozlowska E, Farkkila A, Vallius T, et al
    Mathematical modeling predicts response to chemotherapy and drug combinations in ovarian cancer.
    Cancer Res. 2018 May 16. pii: 0008-5472.CAN-17-3746.
    PubMed     Text format     Abstract available


  39. SALEM M, O'Brien JA, Bernaudo S, Shawer H, et al
    miRNA-590-3p promotes ovarian cancer growth and metastasis via a novel FOXA2-versican pathway.
    Cancer Res. 2018 May 10. pii: 0008-5472.CAN-17-3014.
    PubMed     Text format     Abstract available


  40. CARROLL MJ, Fogg KC, Patel HA, Krause HB, et al
    Alternatively activated macrophages upregulate mesothelial expression of P-selectin to enhance adhesion of ovarian cancer cells.
    Cancer Res. 2018 May 8. pii: 0008-5472.CAN-17-3341.
    PubMed     Text format     Abstract available


  41. LUO XL, Deng C, Su XD, Wang F, et al
    Loss of MED12 induces tumor dormancy in human epithelial ovarian cancer via downregulation of EGFR.
    Cancer Res. 2018 May 7. pii: 0008-5472.CAN-18-0134.
    PubMed     Text format     Abstract available



  42. Correction: Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERalpha in Tamoxifen-Associated Endometrial Carcinomas.
    Cancer Res. 2018;78:2446.
    PubMed     Text format    


    April 2018
  43. CASTLE PE
    Charting the Future of Cancer Health Disparities Research-Letter.
    Cancer Res. 2018;78:1883-1885.
    PubMed     Text format    


  44. SHARMA SK, Chow A, Monette S, Vivier D, et al
    Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.
    Cancer Res. 2018;78:1820-1832.
    PubMed     Text format     Abstract available


  45. SAINI U, Suarez AA, Naidu S, Wallbillich JJ, et al
    STAT3/PIAS3 Levels Serve as "Early Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube.
    Cancer Res. 2018;78:1739-1750.
    PubMed     Text format     Abstract available


    March 2018
  46. CONDELLO S, Sima LE, Ivan C, Cardenas H, et al
    Tissue transglutaminase regulates interactions between ovarian cancer stem cells and the tumor niche.
    Cancer Res. 2018 Mar 6. pii: 0008-5472.CAN-17-2319.
    PubMed     Text format     Abstract available


    January 2018
  47. HA JH, Radhakrishnan R, Jayaraman M, Yan M, et al
    Lysophosphatidic Acid Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response.
    Cancer Res. 2018 Jan 31. pii: 0008-5472.CAN-17-1624.
    PubMed     Text format     Abstract available


  48. ZHANG Y, Li L, Wang L, Li J, et al
    Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer.
    Cancer Res. 2018 Jan 26. pii: 0008-5472.CAN-17-2460.
    PubMed     Text format     Abstract available


  49. CURRY E, Zeller C, Masrour N, Patten D, et al
    Genes predisposed to DNA hypermethylation during acquired resistance to chemotherapy are identified in ovarian tumors by bivalent chromatin domains at initial diagnosis.
    Cancer Res. 2018 Jan 16. pii: 0008-5472.CAN-17-1650.
    PubMed     Text format     Abstract available


  50. RASHMI R, Huang X, Floberg JM, Elhammali A, et al
    Radio-resistant Cervical Cancers Are Sensitive to Inhibition of Glycolysis and Redox Metabolism.
    Cancer Res. 2018 Jan 16. pii: 0008-5472.CAN-17-2367.
    PubMed     Text format     Abstract available


  51. LU Y, Hu Z, Mangala LS, Stine ZE, et al
    MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.
    Cancer Res. 2018;78:64-74.
    PubMed     Text format     Abstract available


    December 2017
  52. KANG J, Shin SH, Yoon H, Huh J, et al
    FIH is an oxygen sensor in ovarian cancer for G9a/GLP-driven epigenetic regulation of metastasis-related genes.
    Cancer Res. 2017 Dec 19. pii: 0008-5472.CAN-17-2506.
    PubMed     Text format     Abstract available


  53. SHANG C, Wang W, Liao Y, Chen Y, et al
    LNMICC promotes nodal metastasis of cervical cancer by reprogramming fatty acid metabolism.
    Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-2356.
    PubMed     Text format     Abstract available


  54. FANG F, Cardenas H, Huang H, Jiang G, et al
    Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Re-sensitization to Platinum Drugs.
    Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-1492.
    PubMed     Text format     Abstract available


    November 2017
  55. HIRAMATSU K, Serada S, Enomoto T, Takahashi Y, et al
    LSR antibody therapy inhibits ovarian epithelial tumor growth by inhibiting lipid uptake.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0910.
    PubMed     Text format     Abstract available


    October 2017
  56. HOUSE CD, Jordan E, Hernandez L, Ozaki M, et al
    NF-kB promotes ovarian tumorigenesis via classical pathways supporting proliferative cancer cells and alternative pathways supporting ALDH+ cancer stem-like cells.
    Cancer Res. 2017 Oct 26. pii: canres.0366.2017.
    PubMed     Text format     Abstract available


  57. WU X, Serna VA, Thomas J, Qiang W, et al
    Subtype-specific cancer-associated fibroblasts contribute to the pathogenesis of uterine leiomyoma.
    Cancer Res. 2017 Oct 20. pii: canres.1744.2017.
    PubMed     Text format     Abstract available


  58. PAYEN VL, Hsu MY, Radecke KS, Wyart E, et al
    Monocarboxylate Transporter MCT1 Promotes Tumor Metastasis Independently of Its Activity as a Lactate Transporter.
    Cancer Res. 2017;77:5591-5601.
    PubMed     Text format     Abstract available


  59. CICHOCKI F, Valamehr B, Bjordahl R, Zhang B, et al
    GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.
    Cancer Res. 2017;77:5664-5675.
    PubMed     Text format     Abstract available


  60. LAMICHHANE P, Karyampudi L, Shreeder B, Krempski J, et al
    IL-10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer.
    Cancer Res. 2017 Oct 9. pii: canres.0740.2017.
    PubMed     Text format     Abstract available


  61. GALL VA, Philips AV, Qiao N, Clise-Dwyer K, et al
    Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.
    Cancer Res. 2017;77:5374-5383.
    PubMed     Text format     Abstract available


    September 2017
  62. YIN X, Jing Y, Cai MC, Ma P, et al
    Clonality, heterogeneity and evolution of synchronous bilateral ovarian cancer.
    Cancer Res. 2017 Sep 28. pii: canres.1461.2017.
    PubMed     Text format     Abstract available


  63. FALCETTA F, Bizzaro F, D'Agostini E, Bani MR, et al
    Modeling cytostatic and cytotoxic responses to new treatment regimens for ovarian cancer.
    Cancer Res. 2017 Sep 26. pii: canres.1099.2017.
    PubMed     Text format     Abstract available



  64. Retraction: CYP1B1 Gene Polymorphisms Have Higher Risk for Endometrial Cancer, and Positive Correlations with Estrogen Receptor alpha and Estrogen Receptor beta Expressions.
    Cancer Res. 2017;77:5211.
    PubMed     Text format    


  65. SONG KH, Choi CH, Lee HJ, Oh SJ, et al
    HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells.
    Cancer Res. 2017;77:5039-5053.
    PubMed     Text format     Abstract available


    July 2017
  66. PIACENTE F, Caffa I, Ravera S, Sociali G, et al
    Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
    Cancer Res. 2017;77:3857-3869.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: